Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol - AstraZeneca

Next Previous
Drug Profile

Budesonide/formoterol - AstraZeneca

Alternative Names: Alenia; Formoterol/budesonide; Symbicort; Symbicort pMDI; Symbicort SMART; Symbicort Turbuhaler

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biosintetica
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Feb 2025 AstraZeneca completes the phase III trial in Asthma (In adolescents, In children, In the elderly, In adults) in Japan, Vietnam, Spain, Canada, Italy, USA, Germany (Inhalation) (EudraCT2021-002026-24) (NCT05202262)
  • 07 Feb 2025 AstraZeneca initiates the EFFICIENCY clinical trial in Asthma in China (Inhalation) (NCT06590740)
  • 19 Nov 2024 AstraZeneca completes phase-III LITHOS trial for Asthma (In adolescents, In children, In the elderly, In adults) in USA, Germany, Canada and Check republic (Inhalation)(NCT05755906)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top